777
Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
 MS patients: Subject; proteinuria and nephrotic syndrome: Effect; IFN-beta-1b: Treatment; IFN-beta-1b: Treatment.Drug; MS: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 MS patients: Subject; proteinuria and nephrotic syndrome: Effect; IFN-beta-1b: Treatment; IFN-beta-1b: Treatment.Drug; MS: Treatment.Disorder